Androgen Deprivation Therapy Does Not Impact Cause-Specific or Overall Survival in High-Risk Prostate Cancer Managed With Brachytherapy and Supplemental External Beam

International Journal of Radiation Oncology Biology Physics

Volumn 68, Issue 1, 2007, Pages 34-40

  Merrick, Gregory S ^a   Butler, Wayne M ^a   Wallner, Kent E ^b   Galbreath, Robert W ^a,c   Allen, Zachariah A ^a   Adamovich, Edward ^d   Lief, Jonathan ^a  

^a WHEELING JESUIT UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Ohio University Eastern   (United States)

^d WHEELING HOSPITAL   (United States)

Author keywords

Androgen deprivation therapy; Brachytherapy; Prostate cancer; Survival

Indexed keywords

BIOPSY; DOSIMETRY; HEALTH CARE; LINEAR REGRESSION; MEDICAL PROBLEMS; PULMONARY DISEASES; RADIOTHERAPY; TUMORS;

ANDROGEN DEPRIVATION THERAPY; BIOCHEMICAL PROGRESSION-FREE SURVIVAL (BPFS); BRACHYTHERAPY; PROSTATE CANCER; SURVIVAL;

ONCOLOGY;

ANDROGEN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; DIABETES MELLITUS; DOSIMETRY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE BIOPSY; PROSTATE CANCER; SECOND CANCER; TREATMENT DURATION;

AGED; ANDROGEN ANTAGONISTS; BRACHYTHERAPY; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS;

EID: 34247110802     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2006.11.046     Document Type: Article

References (31)

1. Partin A.W., Mangold L.A., Lamm D.M., et al. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 58 (2001) 843-848
2. Gancarczyk K.J., Wu H., McLeod G.G., et al. Using the percentage of biopsy cores positive for cancer, pretreatment PSA, and highest biopsy Gleason sum to predict pathologic stage after radical prostatectomy: The center for prostate disease research nomograms. Urology 61 (2004) 589-595
3. D'Amico A.V., Whittington R., Malkowica S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280 (1998) 969-974
4. Hakenberg O.W., Wirth M.P., Hermann T., et al. Recommendations for the treatment of localized prostate cancer by permanent interstitial brachytherapy. Urol Int 70 (2003) 15-20
5. Crook J., Lukka H., Klotz L., et al. Systematic overview of the evidence for brachytherapy in clinically localized prostate cancer. CMAJ 164 (2001) 975-981
6. Blasko J.C., Grimm P.D., Sylvester J.E., et al. Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys 46 (2000) 839-850
7. Dattoli M., Wallner K., True L., et al. Long-term outcomes after treatment with external beam radiation therapy and palladium 103 for patients with higher risk prostate carcinoma. Cancer 97 (2003) 979-983
8. Merrick G.S., Butler W.M., Wallner K.E., et al. Permanent interstitial brachytherapy for clinically organ-confined high-grade prostate cancer with pretreatment PSA < 20 ng/mL. Am J Clin Oncol 27 (2004) 611-615
9. Merrick G.S., Butler W.M., Wallner K.E., et al. Androgen-deprivation therapy does not impact cause-specific or overall survival after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 65 (2006) 669-670
10. Merrick G.S., Butler W.M., Wallner K.E., et al. Prognostic significance of percent positive biopsies in clinically organ-confined prostate cancer treated with permanent prostate brachytherapy with or without supplemental external beam radiation. Cancer J 10 (2004) 54-60
11. Stock R., Cahlon O., Cesaretti J., et al. Combined modality treatment in the management of high-risk prostate cancer. Int J Radiat Oncol Biol Phys 59 (2004) 1352-1359
12. Potters L., Morgenstern C., Calugaru E., et al. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 173 (2005) 1562-1566
13. Merrick G.S., Butler W.M., Wallner K.E., et al. Extracapsular radiation dose distribution following permanent prostate brachytherapy. Am J Clin Oncol 26 (2003) E178-E189
14. Choi S., Wallner K.E., Merrick G.S., et al. Treatment margins predict biochemical outcomes after prostate brachytherapy. Can J 10 (2004) 175-180
15. Sathya J.R., Davis I.R., Julian J.A., et al. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol 23 (2005) 1192-1199
16. Zelefsky M.J., Fuks Z., Hunt M., et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 166 (2001) 876-881
17. Stock R., Stone N., Tabert A., et al. A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys 41 (1998) 101-108
18. Kollmeier M.A., Stock R.G., and Stone N.N. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: Importance of patient selection and implant quality. Int J Radiat Oncol Biol Phys 57 (2003) 645-653
19. Martinez A.A., Gustafson G., Gonzales J., et al. Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer. Int J Radiat Oncol Biol Phys 53 (2002) 316-327
20. Valicenti R., Lu J., Pilepich M., et al. Survival advantage from higher-dose radiation therapy for clinically localized prostate cancer treated in the Radiation Therapy Oncology Group trials. J Clin Oncol 18 (2000) 2740-2746
21. Do T.M., Parker R.G., Smith R.B., et al. High-grade carcinoma of the prostate: A comparison of current local therapies. Urology 57 (2001) 1121-1127
22. Lee L., Stock R.G., and Stone N.N. Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation. Int J Radiat Oncol Biol Phys 52 (2002) 444-452
23. Merrick G.S., Butler W.M., Galbreath R.W., et al. Does hormonal manipulation in conjunction with permanent interstitial brachytherapy, with or without supplemental external beam irradiation, improve the biochemical outcome for men with intermediate or high-risk prostate cancer?. BJU 91 (2003) 23-29
24. Potters L., Torre T., Ashley R., et al. Examining the role of neoadjuvant androgen deprivation in patients undergoing prostate brachytherapy. J Clin Oncol 18 (2000) 1187-1192
25. Merrick G.S., and Butler W.M. Modified uniform seed loading for prostate brachytherapy: Rationale, design and evaluation. Tech Urol 6 (2000) 78-84
26. Nath R., Anderson L.L., Luxton G., et al. Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. Med Phys 22 (1995) 209-234
27. Beyer D.C., McKeogh T., and Thomas T. The impact of short course hormonal therapy on overall and cause-specific survival after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 61 (2005) 1299-1305
28. Merrick GS, Galbreath RW, Butler WM, et al. Obesity is not predictive of overall survival following permanent prostate brachytherapy. Submitted.
29. Merrick G.S., Butler W.M., Wallner K.E., et al. Long-term urinary quality of life after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 56 (2003) 454-461
30. Merrick G.S., Butler W.M., Wallner K.E., et al. Erectile function after prostate brachytherapy. Int J Radiat Oncol Biol Phys 62 (2005) 437-447
31. Merrick G.S., Butler W.M., Wallner K.E., et al. Long-term rectal function following permanent prostate brachytherapy. Can J Sci Am (2007) In press.